Search

Your search keyword '"Merli, Francesco"' showing total 420 results
Start Over Author "Merli, Francesco" Language english
420 results on '"Merli, Francesco"'

1. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

Author

Pulsoni, Alessandro, Ferrero, Simone, Tosti, Maria Elena, Luminari, Stefano, Dondi, Alessandra, Cavallo, Federica, Merli, Francesco, Liberati, Anna Marina, Cenfra, Natalia, Renzi, Daniela, Zanni, Manuela, Boccomini, Carola, Ferreri, Andrés J M, Rattotti, Sara, Zilioli, Vittorio Ruggero, Bolis, Silvia Anna, Bernuzzi, Patrizia, Musuraca, Gerardo, Gaidano, Gianluca, Perrone, Tommasina, Stelitano, Caterina, Tucci, Alessandra, Corradini, Paolo, Bigliardi, Sara, Re, Francesca, Cencini, Emanuele, Mannarella, Clara, Mannina, Donato, Celli, Melania, Tani, Monica, Annechini, Giorgia, Assanto, Giovanni Manfredi, Grapulin, Lavinia, Guarini, Anna, Cavalli, Marzia, De Novi, Lucia Anna, Bomben, Riccardo, Ciabatti, Elena, Genuardi, Elisa, Drandi, Daniela, Della Starza, Irene, Arcaini, Luca, Ricardi, Umberto, Gattei, Valter, Galimberti, Sara, Ladetto, Marco, Foà, Robin, and Del Giudice, Ilaria

Published
2024
Full Text
View/download PDF

2. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

Author

Conconi, Annarita, Chiappella, Annalisa, Ferreri, Andrés J. M., Stathis, Anastasios, Botto, Barbara, Sassone, Marianna, Gaidano, Gianluca, Balzarotti, Monica, Merli, Francesco, Tucci, Alessandra, Vanazzi, Anna, Tani, Monica, Bruna, Riccardo, Orsucci, Lorella, Cabras, Maria Giuseppina, Celli, Melania, Annibali, Ombretta, Liberati, Anna Marina, Zanni, Manuela, Ghiggi, Chiara, Pisani, Francesco, Pinotti, Graziella, Dore, Fausto, Esposito, Fabiana, Pirosa, Maria Cristina, Cesaretti, Marina, Bonomini, Luisella, Vitolo, Umberto, and Zucca, Emanuele

Published
2024
Full Text
View/download PDF

3. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Author

Nastoupil, Loretta J., Hess, Georg, Pavlovsky, Miguel A., Danielewicz, Iwona, Freeman, Jane, García-Sancho, Alejandro Martin, Glazunova, Valeria, Grigg, Andrew, Hou, Jing-Zhou, Janssens, Ann, Kim, Seok Jin, Masliak, Zvenyslava, McKay, Pam, Merli, Francesco, Munakata, Wataru, Nagai, Hirokazu, Özcan, Muhit, Preis, Meir, Wang, Tingyu, Rowe, Melissa, Tamegnon, Monelle, Qin, Rui, Henninger, Todd, Curtis, Madeliene, Caces, Donne Bennett, Thieblemont, Catherine, and Salles, Gilles

Published
2023
Full Text
View/download PDF

4. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Author

Gini, Guido, Tani, Monica, Tucci, Alessandra, Marcheselli, Luigi, Cesaretti, Marina, Bellei, Monica, Pascarella, Anna, Ballerini, Filippo, Petrini, Mauro, Merli, Francesco, Olivieri, Attilio, Lanza, Francesco, Annibali, Ombretta, Zilioli, Vittorio Ruggero, Liberati, Anna Marina, Tisi, Maria Chiara, Arcari, Annalisa, Marino, Dario, Musuraca, Gerardo, Pavone, Vincenzo, Fabbri, Alberto, Pozzi, Samantha, Mannina, Donato, Plenteda, Caterina, Celli, Melania, and Luminari, Stefano

Published
2023
Full Text
View/download PDF

5. A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma

Author

Arcari, Annalisa, Rigacci, Lugi, Tucci, Alessandra, Puccini, Benedetta, Usai, Sara Veronica, Cavallo, Federica, Fabbri, Alberto, Balzarotti, Monica, Pelliccia, Sabrina, Luminari, Stefano, Pennese, Elsa, Zilioli, Vittorio Ruggero, Mahmoud, Abdurraouf Mokhtar, Musuraca, Gerardo, Marino, Dario, Sartori, Roberto, Botto, Barbara, Gini, Guido, Zanni, Manuela, Hohaus, Stefan, Tarantini, Giuseppe, Flenghi, Leonardo, Tani, Monica, Di Rocco, Alice, Merli, Michele, Vallisa, Daniele, Pagani, Chiara, Nassi, Luca, Dessì, Daniela, Ferrero, Simone, Cencini, Emanuele, Bernuzzi, Patrizia, Mammi, Caterina, Marcheselli, Luigi, Tabanelli, Valentina, Spina, Michele, and Merli, Francesco

Published
2023
Full Text
View/download PDF

6. Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL

Author

Tisi, Maria Chiara, Moia, Riccardo, Patti, Caterina, Evangelista, Andrea, Ferrero, Simone, Spina, Michele, Tani, Monica, Botto, Barbara, Celli, Melania, Puccini, Benedetta, Cencini, Emanuele, Di Rocco, Alice, Chini, Claudio, Ghiggi, Chiara, Zambello, Renato, Zanni, Manuela, Sciarra, Roberta, Bruna, Riccardo, Ferrante, Martina, Pileri, Stefano Alessandro, Quaglia, Francesca Maria, Stelitano, Caterina, Re, Alessandro, Volpetti, Stefano, Zilioli, Vittorio Ruggero, Arcari, Annalisa, Merli, Francesco, and Visco, Carlo

Published
2023
Full Text
View/download PDF

9. Neurovascular Manifestations of Sickle Cell Disease.

Author

Zedde, Marialuisa, Quaresima, Micol, Capodanno, Isabella, Grisendi, Ilaria, Assenza, Federica, Napoli, Manuela, Moratti, Claudio, Pavone, Claudio, Bonacini, Lara, Di Cecco, Giovanna, D'Aniello, Serena, Valzania, Franco, Merli, Francesco, and Pascarella, Rosario

Subjects
SICKLE cell anemia, INTRACRANIAL hemorrhage, CEREBRAL infarction, HEMOGLOBINOPATHY, INTRACRANIAL aneurysms
Abstract

Sickle cell disease (SCD) is a hereditary blood disorder characterized by abnormal hemoglobin, leading to the sickle shape of red blood cells. It has several vascular complications and the cerebrovascular ones are among the most frequent and severe both in children and in adults. This review summarizes the main neurovascular manifestations of SCD, including acute stroke, silent cerebral infarction, large-vessel diseases (moyamoya arteriopathy and aneurysms), and brain bleeding. Both epidemiology, pathophysiology, and treatment issues are addressed and prevention of cerebrovascular events, including silent cerebral infarctions, is particularly relevant in SCD patients, being associated to poor functional outcome and cognitive complaints. Transfusions and hydroxyurea are the main available therapy at the moment, but contraindications, availability, and complications might prevent their long term use, particularly in low-income countries. The role of transcranial Doppler in monitoring the patients (mainly children) is analyzed and a practical approach has been selected in order to give the main messages from the current literature for a better management of SCD patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Atypical Presentation of Invasive Aspergillosis during Treatment with Mogamulizumab.

Author

Pavone, Paolo, Arletti, Laura, Ilariucci, Fiorella, Albano, Tommaso, Lusetti, Deborah, Corsini, Romina, Merli, Francesco, and Mezzadri, Sergio

Subjects
PULMONARY aspergillosis, IMMUNE reconstitution inflammatory syndrome, MYCOSIS fungoides, DISEASE progression, PULMONARY nodules
Abstract

Treatment with CCR-4 antagonists has been shown to be protective against the development of invasive pulmonary aspergillosis in animal models. Herein, we present a case of fatal invasive pulmonary aspergillosis in a patient receiving Mogamulizumab. A 64-year-old man with refractory mycosis fungoides was found to have diffuse bilateral pulmonary nodules during a chest CT in June 2022. Bronchoalveolar lavage (BAL) fungal and bacterial cultures and galactomannan were negative, as well as serum beta-glucan and galactomannan. Histology showed a lymphoid infiltrate with a negative fungal stain, so a presumptive diagnosis of lymphoma infiltration was made, and the patient started the CCR-4 antagonist Mogamulizumab treatment in August 2022. He had no symptoms until November when he presented to the hematology clinic reporting dyspnea. He had neutrophilic leukocytosis (18.610 cells/µL), his c-reactive protein was 27 mg/dL, and his skin lesions from mycosis fungoides were just starting to improve. A CT scan showed large diffuse bilateral severely necrotic cavitated lesions with thick walls and apparently synchronous evolution. Beta-glucan was 31 pg/mL (wako method), while serum galactomannan 3.6. BAL was positive for Aspergillus fumigatus culture and galactomannan. Patient started voriconazole but, despite being in a stable condition, he suddenly died after two days. Discussion: Paradoxically, worsening of the chronic pulmonary aspergillosis has been reported after nivolumab treatment, and immune reconstitution syndromes are usually seen during neutrophil recovery after intensive chemotherapy. Our patient already presented indolent lung lesions from 5 months before and he remained completely asymptomatic until the aspergillosis diagnosis when he quickly passed away. Even if a progression of the lesions was expected in 5 months, this case had an atypical presentation. During the 5-month period, he had no pulmonary symptoms, and his c-reactive protein was negative. Furthermore, in the setting of the natural progression of subacute/chronic aspergillosis, a different radiological picture was expected with a less severe and probably asynchronous evolution. We think that the immune restoration associated with Mogamulizumab (also supported by the concurrent clinical response of the skin lesions) could have been detrimental in this case, exacerbating a catastrophic immune response or alternatively masquerading the clinical progression of aspergillosis. Clinicians should be aware of immune reconstitution syndromes possibly leading to fatal outcomes in immunocompromised patients starting CCR-4 antagonists. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

Author

Visco, Carlo, Marcheselli, Luigi, Mina, Roberto, Sassone, Marianna, Guidetti, Anna, Penna, Domenico, Cattaneo, Chiara, Bonuomo, Valentina, Busca, Alessandro, Ferreri, Andrés José María, Bruna, Riccardo, Petrucci, Luigi, Cairoli, Roberto, Salvini, Marco, Bertù, Lorenza, Ladetto, Marco, Pilerci, Sofia, Pinto, Antonello, Ramadan, Safaa, Marchesi, Francesco, Cavo, Michele, Arcaini, Luca, Coviello, Elisa, Romano, Alessandra, Musto, Pellegrino, Massaia, Massimo, Fracchiolla, Nicola, Marchetti, Monia, Scattolin, Annamaria, Tisi, Maria Chiara, Cuneo, Antonio, Della Porta, Matteo, Trentin, Livio, Turrini, Marco, Gherlinzoni, Filippo, Tafuri, Agostino, Galimberti, Sara, Bocchia, Monica, Cardinali, Valeria, Cilloni, Daniela, Corso, Alessandro, Armiento, Daniele, Rigacci, Luigi, La Barbera, Elettra Ortu, Gambacorti-Passerini, Carlo, Visani, Giuseppe, Vallisa, Daniele, Venditti, Adriano, Selleri, Carmine, Conconi, Annarita, Tosi, Patrizia, Lanza, Francesco, Candoni, Anna, Krampera, Mauro, Corradini, Paolo, Passamonti, Francesco, and Merli, Francesco

Published
2022
Full Text
View/download PDF

12. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

Author

Santoro, Armando, Mazza, Rita, Spina, Michele, Califano, Catello, Specchia, Giorgina, Carella, Michele, Consoli, Ugo, Palombi, Francesca, Musso, Maurizio, Pulsoni, Alessandro, Kovalchuk, Sofya, Bonfichi, Maurizio, Ricci, Francesca, Fabbri, Alberto, Liberati, Anna Marina, Rodari, Marcello, Giordano, Laura, Chimienti, Emanuela, Balzarotti, Monica, Sorasio, Roberto, Gallamini, Andrea, Ghiggi, Chiara, Ciammella, Patrizia, Ricardi, Umberto, Chauvie, Stephane, Carlo-Stella, Carmelo, and Merli, Francesco

Published
2021
Full Text
View/download PDF

13. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Author

Passamonti, Francesco, Cattaneo, Chiara, Arcaini, Luca, Bruna, Riccardo, Cavo, Michele, Merli, Francesco, Angelucci, Emanuele, Krampera, Mauro, Cairoli, Roberto, Della Porta, Matteo Giovanni, Fracchiolla, Nicola, Ladetto, Marco, Gambacorti Passerini, Carlo, Salvini, Marco, Marchetti, Monia, Lemoli, Roberto, Molteni, Alfredo, Busca, Alessandro, Cuneo, Antonio, Romano, Alessandra, Giuliani, Nicola, Galimberti, Sara, Corso, Alessandro, Morotti, Alessandro, Falini, Brunangelo, Billio, Atto, Gherlinzoni, Filippo, Visani, Giuseppe, Tisi, Maria Chiara, Tafuri, Agostino, Tosi, Patrizia, Lanza, Francesco, Massaia, Massimo, Turrini, Mauro, Ferrara, Felicetto, Gurrieri, Carmela, Vallisa, Daniele, Martelli, Maurizio, Derenzini, Enrico, Guarini, Attilio, Conconi, Annarita, Cuccaro, Annarosa, Cudillo, Laura, Russo, Domenico, Ciambelli, Fabrizio, Scattolin, Anna Maria, Luppi, Mario, Selleri, Carmine, Ortu La Barbera, Elettra, Ferrandina, Celestino, Di Renzo, Nicola, Olivieri, Attilio, Bocchia, Monica, Gentile, Massimo, Marchesi, Francesco, Musto, Pellegrino, Federici, Augusto Bramante, Candoni, Anna, Venditti, Adriano, Fava, Carmen, Pinto, Antonio, Galieni, Piero, Rigacci, Luigi, Armiento, Daniele, Pane, Fabrizio, Oberti, Margherita, Zappasodi, Patrizia, Visco, Carlo, Franchi, Matteo, Grossi, Paolo Antonio, Bertù, Lorenza, Corrao, Giovanni, Pagano, Livio, and Corradini, Paolo

Published
2020
Full Text
View/download PDF

15. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Author

Santoro, Armando, Mazza, Rita, Pulsoni, Alessandro, Re, Alessandro, Bonfichi, Maurizio, Zilioli, Vittorio Ruggero, Zanni, Manuela, Merli, Francesco, Anastasia, Antonella, Luminari, Stefano, Annechini, Giorgia, Gotti, Manuel, Peli, Annalisa, Liberati, Anna Marina, Di Renzo, Nicola, Castagna, Luca, Giordano, Laura, Ricci, Francesca, and Carlo-Stella, Carmelo

Published
2020
Full Text
View/download PDF

16. The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK− anaplastic large cell lymphoma by regulating the DNA helicase HELLS

Author

Fragliasso, Valentina, Verma, Akanksha, Manzotti, Gloria, Tameni, Annalisa, Bareja, Rohan, Heavican, Tayla B., Iqbal, Javeed, Wang, Rui, Fiore, Danilo, Mularoni, Valentina, Chan, Wing C., Lhoumaud, Priscillia, Skok, Jane, Zanetti, Eleonora, Merli, Francesco, Ciarrocchi, Alessia, Elemento, Oliver, and Inghirami, Giorgio

Published
2020
Full Text
View/download PDF

17. Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the “Gruppo Italiano Trapianto di Midollo Osseo”

Author

Botti, Stefano, Agreiter, Iris, Orlando, Laura, Gargiulo, Gianpaolo, Bonifazi, Francesca, Banfi, Marina Marialuisa, Cappucciati, Lorella, Caffarri, Cristiana, De Cecco, Valentina, Deiana, Giuseppe Marco, Gavezzotti, Marta, Magarò, Antonio, Netti, Maria Giovanna, Pignatelli, Adriana Concetta, Rostagno, Elena, Samarani, Emanuela, Cardoso, Janini Silva, Soave, Sonia, Valente, Concetta Maria, Vedovetto, Alessio, Zecca, Marco, Luminari, Stefano, Merli, Francesco, and Guberti, Monica

Published
2020
Full Text
View/download PDF

20. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.

Author

Federico, Massimo, Fortpied, Catherine, Stepanishyna, Yana, Gotti, Manuel, van der Maazen, Richard, Cristinelli, Caterina, Re, Alessandro, Plattel, Wouter, Lazarovici, Julien, Merli, Francesco, Specht, Lena, Schiano de Colella, Jean-Marc, Hutchings, Martin, Versari, Annibale, Edeline, Véronique, Stamatoulas, Aspasia, Girinsky, Theodore, Ricardi, Umberto, Aleman, Berthe, and Meulemans, Bart

Published
2024
Full Text
View/download PDF

21. The Role of Geriatric Assessment in the Management of Diffuse Large B-Cell Lymphoma.

Author

Merli, Francesco, Pozzi, Stefano, Catellani, Hillary, Barbieri, Emiliano, and Luminari, Stefano

Subjects
*PATIENT autonomy, *FUNCTIONAL status, *GERIATRIC assessment, *B cell lymphoma, *SARCOPENIA, *DISEASE management, *COMORBIDITY, *OLD age
Abstract

Simple Summary: The treatment choice for an older patient with diffuse large B-cell lymphoma (DLBCL) is challenging due to the complexity of the patient. Among the several available tools to evaluate an older subject with DLBCL, the simplified geriatric assessment (sGA) categorizes patients as fit, unfit, or frail and has been validated to predict the risk of death. The elderly prognostic index (EPI), which combines sGA and IPI scores and hemoglobin level, is the first prognostic score for older patients, with three risk groups for survival. New validated tools will help physicians choose the best treatment for elderly patients with DLBCL, further contributing to improving the personalized approach to elderly subjects. The treatment choice for an older patient with diffuse large B-cell lymphoma (DLBCL) depends on many other factors in addition to age, which alone does not reflect the complexity of the aging process. Functional features and comorbidity incidence differ not only between younger and older patients but also among older patients themselves. The comprehensive geriatric assessment (CGA) quickly evaluates fitness status by investigating the patient's different functional areas, degree of autonomy, and presence of comorbidities. Various tools are available to evaluate frailty; which assessment tool to use should be based on the clinical aim. The simplified geriatric assessment (sGA) from the elderly project by the Fondazione Italiana Linfomi, prospectively tested on the largest number of patients, categorizes patients as fit, unfit, or frail, with a decreasing rate of overall survival. The elderly prognostic index (EPI), which combines sGA and IPI scores and hemoglobin level, is the first prognostic score for older patients, with three risk groups for survival. Future GAs should consider new parameters, including sarcopenia, which appears to be inversely related to survival. New tools based on prospective studies can help physicians choose the best treatment in light of the individual patient's characteristics. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score

Author

Olivieri, Jacopo, Attolico, Immacolata, Nuccorini, Roberta, Pascale, Sara Pasquina, Chiarucci, Martina, Poiani, Monica, Corradini, Paolo, Farina, Lucia, Gaidano, Gianluca, Nassi, Luca, Sica, Simona, Piccirillo, Nicola, Pioltelli, Pietro Enrico, Martino, Massimo, Moscato, Tiziana, Pini, Massimo, Zallio, Francesco, Ciceri, Fabio, Marktel, Sarah, Mengarelli, Andrea, Musto, Pellegrino, Capria, Saveria, Merli, Francesco, Codeluppi, Katia, Mele, Giuseppe, Lanza, Francesco, Specchia, Giorgina, Pastore, Domenico, Milone, Giuseppe, Saraceni, Francesco, Di Nardo, Elvira, Perseghin, Paolo, and Olivieri, Attilio

Published
2018
Full Text
View/download PDF

23. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study

Author

Agostinelli, Claudio, Gallamini, Andrea, Stracqualursi, Luisa, Agati, Patrizia, Tripodo, Claudio, Fuligni, Fabio, Sista, Maria Teresa, Fanti, Stefano, Biggi, Alberto, Vitolo, Umberto, Rigacci, Luigi, Merli, Francesco, Patti, Caterina, Romano, Alessandra, Levis, Alessandro, Trentin, Livio, Stelitano, Caterina, Borra, Anna, Piccaluga, Pier Paolo, Hamilton-Dutoit, Stephen, Kamper, Peter, Zaucha, Jan Maciej, Małkowski, Bogdan, Kulikowski, Waldemar, Tajer, Joanna, Subocz, Edyta, Rybka, Justyna, Steidl, Christian, Broccoli, Alessandro, Argnani, Lisa, Gascoyne, Randy D, d'Amore, Francesco, Zinzani, Pier Luigi, and Pileri, Stefano A

Published
2016
Full Text
View/download PDF

25. Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment.

Author

Penna, Domenico, Tieghi, Alessia, Valli, Riccardo, and Merli, Francesco

Subjects
MYELOFIBROSIS, RUXOLITINIB, THERAPEUTICS, EXTRAMEDULLARY hematopoiesis, BODY temperature, MAGNETIC resonance angiography
Abstract

Allogeneic bone marrow transplant is the only potentially curative treatment, while drug therapies aim only to reduce spleen size, constitutional symptoms, and anemia [[4]]. Standard treatment for AMF involves corticosteroids and immunosuppressive therapies [[9]]. Bone marrow fibrosis (BMF) is usually associated with malignant neoplasms (mainly by myeloproliferative disorders), but in a minority of cases, it is due to non-neoplastic causes [[1]]. Taking the above into account, in September 2015, after six months of steroid suspension and 18 months of continuous Ruxolitinib treatment, it was decided to reevaluate the disease to verify if a clonal process caused the BMF or if the fibrosis was associated with the autoimmune disease. [Extracted from the article]

Published
2023
Full Text
View/download PDF

26. Fertility preservation and monitoring in adult patients diagnosed with lymphoma: consensus-based practical recommendations by the Fondazione Italiana Linfomi & Società Italiana della Riproduzione Umana.

Author

Minoia, Carla, Viviani, Simonetta, Silvestris, Erica, Palini, Simone, Parissone, Francesca, De Palma, Giuseppe, Fedina, Anna, Cormio, Gennaro, Guarini, Attilio, Gini, Guido, Montano, Luigi, Merli, Francesco, and Peccatori, Fedro Alessandro

Subjects
FERTILITY preservation, GENERAL practitioners, HODGKIN'S disease, PATIENT monitoring, LITERATURE reviews
Abstract

Introduction: Fertility preservation (FP) and monitoring has considerable relevance in the multidisciplinary approach to cancer patients. In these consensus-based practical recommendations, the scientific societies Fondazione Italiana Linfomi (FIL) and Società Italiana della Riproduzione Umana (SIRU) reviewed the main aspects and identified the optimal paths which aim to preserve and monitor fertility in patients diagnosed with lymphoma at the different phases of the disease and during long-term survivorship. Methods: For the Panel, eleven experts were selected for their expertise in research and clinical practice on onco-fertility and lymphoma. The Panel's activity was supervised by a chairman. A series of rank-ordering key questions were proposed according to their clinical relevance and discussed among the Panel, focusing on patients diagnosed with non-Hodgkin's lymphomas and Hodgkin lymphoma. Agreement among all the Panelists on the content and terminology of the statements was evaluated by a web-based questionnaire according to the Delphi methodology. Results: From the literature review a total of 78 questions or sentences, divided into the 6 areas of interest, were identified. By applying the Gwet's AC, k was: Section 1: 0,934 (Very good); Section 2: 0,958 (Very good); Section 3: 0,863 (Very good); Section 4: 0,649 (Good); Section 5: 0,936 (Very good); Section 6 raw agreement 100%. Two rounds of Delphi allowed to provide the maximum agreement. All statements were newly discussed in a round robin way and confirmed for the drafting of the final recommendations. Discussion: These recommendations would be useful for onco-hematologists, gynecologists, urologists, and general practice physicians who take care of young lymphoma patients to guarantee an evidence-based oncofertility assessment and treatment during the oncologic pathway. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020.

Author

Mangone, Lucia, Penna, Domenico, Marinelli, Francesco, Roncaglia, Francesca, Bisceglia, Isabella, Merli, Francesco, Ruffini, Alessia, Gamberi, Barbara, Tieghi, Alessia, Valli, Riccardo, Albertazzi, Laura, Iori, Mauro, Rossi, Paolo Giorgi, Vener, Claudia, Morabito, Fortunato, Neri, Antonino, and Luminari, Stefano

Subjects
HEMATOLOGIC malignancies, ACUTE myeloid leukemia, FOLLICULAR lymphoma, HODGKIN'S disease, MYELOPROLIFERATIVE neoplasms
Abstract

Background: Hematological malignancies (HMs) represent a heterogeneous group of diseases with diverse etiology, pathogenesis, and prognosis. HMs' accurate registration by Cancer Registries (CRs) is hampered by the progressive de-hospitalization of patients and the transition to molecular rather than microscopic diagnosis. Material and methods: A dedicated software capable of automatically identifying suspected HMs cases by combining several databases was adopted by Reggio Emilia Province CR (RE-CR). Besides pathological reports, hospital discharge archives, and mortality records, RE-CR retrieved information from general and biomolecular laboratories. Incidence, mortality, and 5-year relative survival (RS) reported according to age, sex, and 4 HMs' main categories, were noted. Results: Overall, 7,578 HM cases were diagnosed from 1996 to 2020 by RE-CR. HMs were more common in males and older patients, except for Hodgkin Lymphoma and Follicular Lymphoma (FL). Incidence showed a significant increase for FL (annual percent change (APC)=3.0), Myeloproliferative Neoplasms (MPN) in the first period (APC=6.0) followed by a significant decrease (APC=-7.4), and Myelodysplastic Syndromes (APC=16.4) only in the first period. Over the years, a significant increase was observed in 5-year RS for Hodgkin -, Marginal Zone -, Follicular - and Diffuse Large B-cell-Lymphomas, MPN, and Acute Myeloid Leukemia. The availability of dedicated software made it possible to recover 80% of cases automatically: the remaining 20% required direct consultation of medical records. Conclusions: The study emphasizes that HM registration needs to collect information from multiple sources. The digitalization of CRs is necessary to increase their efficiency. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Author

Ceriani, Luca, Martelli, Maurizio, Zinzani, Pier Luigi, Ferreri, Andrés J.M., Botto, Barbara, Stelitano, Caterina, Gotti, Manuel, Cabras, Maria Giuseppina, Rigacci, Luigi, Gargantini, Livio, Merli, Francesco, Pinotti, Graziella, Mannina, Donato, Luminari, Stefano, Stathis, Anastasios, Russo, Eleonora, Cavalli, Franco, Giovanella, Luca, Johnson, Peter W.M., and Zucca, Emanuele

Published
2015
Full Text
View/download PDF

33. Transplant results in adults with Fanconi anaemia

Author

Bierings, Marc, Bonfim, Carmem, Peffault De Latour, Regis, Aljurf, Mahmoud, Mehta, Parinda A., Knol, Cora, Boulad, Farid, Tbakhi, Abdelghani, Esquirol, Albert, McQuaker, Grant, Sucak, Gulsan A., Othman, Tarek B., Halkes, Constantijn J. M., Carpenter, Ben, Niederwieser, Dietger, Zecca, Marco, Kröger, Nicolaus, Michallet, Mauricette, Risitano, Antonio M., Ehninger, Gerhard, Porcher, Raphael, Dufour, Carlo, Bonfirm, Carmem, Socié, Gerard, Gurman, Gunham, Ghavamzadeh, Ardesir, Hamladji, Rise‐Marie, van Lint, M.T., Stepensky, Polina, Koh, Mickey, Ozkurt, Zubeyde Nur, Veelken, Joan Hendrik, Bunjes, Donald, Beelen, Dietrich, Campos, Antonio, Robinson, Stephen, Alessandrino, E. Paolo, Unal, Ali, Fernandez Navarro, José Maria, Mufti, G.J., Velardi, Andrea, Passweg, Jakob, Apperley, Jane, Sengeloev, Henrik, Ljungman, Per, Foá, Roberto, Alegre, Adrián, Espiga, Carlos Richard, Cornelissen, J.J., Di Bartolomeo, Paolo, Cordonnier, Catherine, Browne, Paul, Jubert, Charlotte, Gastl, Günther, Pierelli, Luca, Johansson, Jan‐Erik, Fagioli, Franca, Moraleda, José, Zuckerman, Tsila, Bazarbachi, Ali, Sedlacek, Petr, Rössig, Claudia, Wynn, R.F., Hallek, Michael, Toren, Amos, Zudaire, Teresa, Clausen, Joahannes, Spencer, Andrew, Grazon Lopez, Sebastian, Schots, Rik, Komarnicki, M., González Muniz, Soledad, Vitek, Antonin, Rambaldi, Alessandro, Merli, Francesco, Rubio, Marie Thérese, Rossig, Claudia, Cabrera Marín, José Rafael, Porto, Fulvio, Kerre, Tessa, Metzner, Bernd, Stein, Jerry, Bertrand, Yves, Ciceri, Fabio, Chybicka, Alicja, Diez‐Martin, J.L., Bayoumy, Mohamed, de la Fuente, Josu, and Fegueux, Nathalie

Published
2018
Full Text
View/download PDF

34. Biological features and outcome of diffuse large B‐cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.

Author

Arcari, Annalisa, Tabanelli, Valentina, Merli, Francesco, Marcheselli, Luigi, Merli, Michele, Balzarotti, Monica, Zilioli, Vittorio Ruggero, Fabbri, Alberto, Cavallo, Federica, Casaluci, Gloria Margiotta, Tucci, Alessandra, Puccini, Benedetta, Pennese, Elsa, Di Rocco, Alice, Zanni, Manuela, Flenghi, Leonardo, Gini, Guido, Sartori, Roberto, Chiappella, Annalisa, and Usai, Sara Veronica

Subjects
OLDER patients, HEPATITIS C virus, DIFFUSE large B-cell lymphomas, OLDER people, HEPATOTOXICOLOGY
Abstract

Summary: Up to 10%–15% of diffuse large B‐cell lymphoma (DLBCL) are related to hepatitis C virus (HCV) infection, in particular in elderly patients. The Fondazione Italiana Linfomi has recently published a multicentre prospective observational study, the 'Elderly Project', on the outcome of DLBCL in patients aged ≥65 years, evaluated using a simplified comprehensive geriatric assessment. The aim of this study was to compare biological and clinical features of HCV positive (HCV+) with HCV negative (HCV−) cases. A total of 89 HCV+ patients were identified out of 1095 evaluated for HCV serology (8.1%). The HCV+ patients were older, less fit, and had frequent extranodal involvement. The cell‐of‐origin determination by Nanostring showed that HCV+ cases less frequently had an activated B‐cell profile compared to HCV− patients (18% vs. 43%). In all, 86% of HCV+ patients received rituximab‐cyclophosphamide, doxorubicin, vincristine (Oncovin) and prednisone (R‐CHOP)‐like immunochemotherapy. Grade 3–4 liver toxicity occurred in 3% of cases. Among centrally reviewed cases confirmed as DLBCL, the 3‐year overall survival of HCV+ patients was very similar to HCV− (63% vs. 61%, p = 0.926). In all, 20 HCV+ patients were treated with direct‐acting antiviral agents (DAAs), with good tolerance and sustained virological response in all cases. The 3‐year progression‐free survival for this subgroup was excellent (77%), suggesting DAAs' possible role in reducing the risk of relapse by eliminating the viral trigger. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Author

Ferrari, Angela, Rattotti, Sara, Ferrero, Simone, Merli, Michele, Merli, Francesco, Usai, Sara Veronica, Deodato, Marina, Pulsoni, Alessandro, Cencini, Emanuele, Re, Francesca, Tisi, Maria Chiara, Delamain, Marcia Torresan, Spina, Michele, Annibali, Ombretta, Rago, Angela, Boccomini, Carola, Ferreri, Andrés J M, Nizzoli, Maria Elena, Arcaini, Luca, Luminari, Stefano, and Varettoni, Marzia

Published
2022
Full Text
View/download PDF

36. PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)

Author

Balzarotti, Monica, Ricardi, Umberto, Spina, Michele, Evangelista, Andrea, Tucci, Alessandra, Cavallo, Federica, Zanni, Manuela, Arcari, Annalisa, Zilioli, Vittorio Ruggero, Sartori, Roberto, Merli, Francesco, Re, Francesca, Vitolo, Umberto, Deidda, Maria Assunta, Melis, Luca, Dessì, Daniela, Rodari, Marcello, Santoro, Armando, Gaidano, Gianluca, Ciccone, Giovannino, Chauvie, Stephane, and Cabras, Maria Giuseppina

Published
2022
Full Text
View/download PDF

37. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Author

Polverelli, Nicola, Breccia, Massimo, Benevolo, Giulia, Martino, Bruno, Tieghi, Alessia, Latagliata, Roberto, Sabattini, Elena, Riminucci, Mara, Godio, Laura, Catani, Lucia, Nicolosi, Maura, Perricone, Margherita, Sollazzo, Daria, Colafigli, Gioia, Campana, Anna, Merli, Francesco, Vitolo, Umberto, Alimena, Giuliana, Martinelli, Giovanni, Lewis, Russell E., Vianelli, Nicola, Cavo, Michele, and Palandri, Francesca

Published
2017
Full Text
View/download PDF

38. SARS‐CoV‐2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID‐19 cohort.

Author

Merli, Michele, Ferrarini, Isacco, Merli, Francesco, Busca, Alessandro, Mina, Roberto, Falini, Brunangelo, Bruna, Riccardo, Cairoli, Roberto, Marchetti, Monia, Romano, Alessandra, Cavo, Michele, Arcaini, Luca, Trentin, Livio, Cattaneo, Chiara, Derenzini, Enrico, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Scattolin, Annamaria, Billio, Atto, and Bocchia, Monica

Subjects
CHRONIC lymphocytic leukemia, COVID-19, SARS-CoV-2, CHRONIC leukemia, HEMATOLOGY, COVID-19 treatment
Abstract

COVID‐19, the disease caused by SARS‐CoV‐2, is still afflicting thousands of people across the globe. Few studies on COVID‐19 in chronic lymphocytic leukemia (CLL) are available. Here, we analyzed data from the CLL cohort of the Italian Hematology Alliance on COVID‐19 (NCT04352556), which included 256 CLL patients enrolled between 25 February 2020 and 1 February 2021. Median age was 70 years (range 38–94) with male preponderance (60.1%). Approximately half of patients (n = 127) had received at least one line of therapy for CLL, including 108 (83.7%) who were on active treatment at the time of COVID‐19 or received their last therapy within 12 months. Most patients (230/256, 89.9%) were symptomatic at COVID‐19 diagnosis and the majority required hospitalization (n = 176). Overall, after a median follow‐up of 42 days (IQR 24–96), case fatality rate was 30.1%, and it was 37.5% and 24.4% in the first (25 February 2020–22 June 2020) and second wave (23 June 2020–1 February 2021), respectively (p = 0.03). At multivariate analysis, male sex (HR 1.82, 95% CI 1.03–3.24, p = 0.04), age over than 70 years (HR 2.23, 95% CI 1.23–4.05, p = 0.01), any treatment for CLL given in the last 12 months (HR 1.72, 95% CI 1.04–2.84, p = 0.04) and COVID‐19 severity (severe: HR 5.66, 95% CI 2.62–12.33, p < 0.0001; critical: HR 15.99, 95% CI 6.93–36.90, p < 0.0001) were independently associated with poor survival. In summary, we report a dismal COVID‐related outcome in a significant fraction of CLL patients, that can be nicely predicted by clinical parameters. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma

Author

Gobbi, Paolo G., Valentino, Francesco, Bassi, Emilio, Coriani, Chiara, Merli, Francesco, Bonfante, Valeria, Marchianò, Alfonso, Gallamini, Andrea, Bolis, Silvia, Stelitano, Caterina, Levis, Alessandro, Federico, Massimo, Angrilli, Francesco, Di Giulio, Giuseppe, and Corazza, Gino R.

Published
2011
Full Text
View/download PDF

42. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL)

Author

Zallio, Francesco, Tamiazzo, Stefania, Monagheddu, Chiara, Merli, Francesco, Ilariucci, Fiorella, Stelitano, Caterina, Liberati, Anna Marina, Mannina, Donato, Vitolo, Umberto, Angelucci, Emanuele, Scalabrini, Delia Rota, Vallisa, Daniele, Bellei, Monica, Bari, Alessia, Ciccone, Giovannino, Salvi, Flavia, and Levis, Alessandro

Published
2016
Full Text
View/download PDF

43. Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.

Author

Bari, Alessia, Gerardi, Chiara, Allocati, Eleonora, Puzzovivo, Agata, De Sanctis, Vitaliana, Tucci, Alessandra, Balzarotti, Monica, Franceschetti, Silvia, Merli, Francesco, Guarini, Attilio, Gini, Guido, and Minoia, Carla

Subjects
CANCER patient psychology, HODGKIN'S disease, PATIENT aftercare, SPECIALTY hospitals, B cell lymphoma, HEALTH expectancy, TREATMENT effectiveness, CANCER, CANCER treatment, HUMAN services programs, HEMATOLOGIC malignancies, QUALITY of life, SYMPTOMS
Published
2022
Full Text
View/download PDF

44. Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV.

Author

Zappasodi, Patrizia, Cattaneo, Chiara, Valeria Ferretti, Virginia, Mina, Roberto, José María Ferreri, Andrés, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Stefano Fracchiolla, Nicola, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, and Maria Scattolin, Anna

Subjects
HEMATOLOGIC malignancies, COVID-19, ACUTE myeloid leukemia, TREATMENT effectiveness, INFECTION
Abstract

The impact of secondary infections (SI) on COVID‐19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID‐19. Among 1741 HM patients with COVID‐19, 134 (7.7%) had 185 SI, with a 1‐month cumulative incidence of 5%. Median time between COVID‐19 diagnosis and SI was 16 days (IQR: 5–36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID‐19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram‐negative isolates (18.9%), while coagulase‐negative Staphylococci were the most frequent among Gram‐positive (14.2%). The 30‐day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID‐19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL)

Author

Rigacci, Luigi, Puccini, Benedetta, Zinzani, Pier Luigi, Biggi, Alberto, Castagnoli, Antonio, Merli, Francesco, Balzarotti, Monica, Stelitano, Caterina, Spina, Michele, Vitolo, Umberto, Stefoni, Vittorio, Levis, Alessandro, Gotti, Manuel, Rosaria, Sancetta, Maria, Stefani Piero, Bosi, Alberto, and Gallamini, Andrea

Published
2015
Full Text
View/download PDF

46. Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy.

Author

Gozzi, Fabrizio, Aldigeri, Raffaella, Mastrofilippo, Valentina, De Simone, Luca, Bolletta, Elena, Marzano, Jacopo, Iannetta, Danilo, Coassin, Marco, Ilariucci, Fiorella, Ferrari, Angela, Luminari, Stefano, Merli, Francesco, Croci, Stefania, Zerbini, Alessandro, Farnetti, Enrico, Nicoli, Davide, Valli, Riccardo, Tamagnini, Ione, Cavazza, Alberto, and Salvarani, Carlo

Subjects
CANCER chemotherapy, SURVIVAL rate, UVEITIS, LYMPHOMAS, CENTRAL nervous system
Abstract

To investigate the role of combined systemic and local chemotherapy in improving the survival of patients with vitreoretinal lymphoma (VRL). Patients with VRL consecutively seen from 2006 to 2020 were retrospectively reviewed; data on the presence and time of central nervous system (CNS) involvement and treatment regimen (systemic, local or combined chemotherapy) were collected. Overall survival (OS) and progression-free survival (PFS) were calculated for each group. Forty-three eyes of 22 subjects with histology-proven VRL were included. Mean time of survival was 64.8 months (SE±10.8). Twelve patients (57%) presented CNS involvement, which was significantly associated with progression (r = 0.48, P =.03) and death (r = 0.56, P =.009). The isolated primary VRL group had a 5-year OS of 80%. Combined systemic and local chemotherapy reduced the risk of death by 82% (hazard ratio 0.18[0.04– 0.85]) in the entire cohort. Combined systemic and local chemotherapy significantly improved OS but not PFS of patients affected by VRL. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study.

Author

Durmo, Rexhep, Donati, Benedetta, Rebaud, Louis, Cottereau, Anne Segolene, Ruffini, Alessia, Nizzoli, Maria Elena, Ciavarella, Sabino, Vegliante, Maria Carmela, Nioche, Christophe, Meignan, Michel, Merli, Francesco, Versari, Annibale, Ciarrocchi, Alessia, Buvat, Irene, and Luminari, Stefano

Subjects
PROGNOSIS, HODGKIN'S disease, GENE expression profiling, PROGRESSION-free survival, BLEOMYCIN, ACID-base imbalances
Abstract

We evaluated the prognostic role of the largest distance between two lesions (Dmax), defined by positron emission tomography (PET) in a retrospective cohort of newly diagnosed classical Hodgkin Lymphoma (cHL) patients. We also explored the molecular bases underlying Dmax through a gene expression analysis of diagnostic biopsies. We included patients diagnosed with cHL from 2007 to 2020, initially treated with ABVD, with available baseline PET for review, and with at least two FDG avid lesions. Patients with available RNA from diagnostic biopsy were eligible for gene expression analysis. Dmax was deduced from the three‐dimensional coordinates of the baseline metabolic tumor volume (MTV) and its effect on progression free survival (PFS) was evaluated. Gene expression profiles were correlated with Dmax and analyzed using CIBERSORTx algorithm to perform deconvolution. The study was conducted on 155 eligible cHL patients. Using its median value of 20 cm, Dmax was the only variable independently associated with PFS (HR = 2.70, 95% CI 1.1–6.63, pValue = 0.03) in multivariate analysis of PFS for all patients and for those with early complete metabolic response (iPET‐). Among patients with iPET‐low Dmax was associated with a 4‐year PFS of 90% (95% CI 82.0–98.9) significantly better compared to high Dmax (4‐year PFS 72.4%, 95% CI 61.9–84.6). From the analysis of gene expression profiles differences in Dmax were mostly associated with variations in the expression of microenvironmental components. In conclusion our results support tumor dissemination measured through Dmax as novel prognostic factor for cHL patients treated with ABVD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trialof the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Author

Ferrario, Andrea, Merli, Francesco, Luminari, Stefano, Stelitano, Caterina, Mannina, Donato, Russo, Mario, Mazza, Patrizio, Marcheselli, Luigi, Goldaniga, Maria Cecilia, Federico, Massimo, Baldini, Luca, and for the Gruppo Italiano per lo Studio dei Linfomi

Published
2011
Full Text
View/download PDF

49. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi

Author

Merli, Francesco, Cavallo, Federica, Salvi, Flavia, Tucci, Alessandra, Musuraca, Gerardo, Nassi, Luca, Merli, Michele, Tani, Monica, Gini, Guido, Ferrari, Angela, Molinari, Anna Lia, Liberati, Anna Marina, Conconi, Annarita, Matteucci, Paola, Bari, Alessia, Scalone, Renato, Ferrero, Simone, Zanni, Manuela, Mammi, Caterina, and Luminari, Stefano

Published
2020
Full Text
View/download PDF

50. Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III–IV and no impact on relapse and overall survival.

Author

Guidotti, Samantha, Bassi, Simona, Rossi, Angela, Borotti, Elena, Cortellazzi, Pilade, Ferrarese, Diego, Ronda, Elena, Scarpa, Alice, Schiro, Alice, Merli, Francesco, Prezioso, Lucia, Bonifazi, Francesca, Narni, Franco, Fabrizi, Enrico, and Vallisa, Daniele

Subjects
STEM cell transplantation, BONE marrow cells, HEMATOPOIETIC stem cell transplantation, T cells, OVERALL survival
Abstract

Objectives: Early chimerism analysis is important to assess engraftment in allogeneic hematopoietic stem cell transplantations. Methods: We retrospectively investigated the impact of T‐cell chimerism at day 30 in bone marrow on acute graft‐versus‐host disease (aGVHD), relapse, and overall survival in 142 adult allo‐transplanted patients. Results: The majority of patients (89%) received myeloablative conditioning and 90% have undergone T‐cell replete donor graft. At day 30, 103 patients showed T‐complete chimerism with prevalence in haploidentical transplants, whereas 39 cases had CD3+ mixed chimerism, including 30 patients transplanted with HLA identical donors, and 21 with T‐cell donors<90%. T‐cell chimerism at day 30 was weakly inversely related to aGVHD grades II–IV (p =.078) with no cases of grades III–IV aGVHD in patients with CD3+ <95%. Mixed T‐cell chimerism did not impact on relapse (p =.448) and five of the seven patients who relapsed had T‐cell chimerism ≤90%. Older age and active disease at transplant had a statistically significant negative effect on overall survival (p =.01 and p =.0001, respectively), whereas mixed CD3+ chimerism did not. Conclusions: T lymphocyte chimerism analysis at day +30 in bone marrow could identify allo‐transplanted patients at major risk of aGVHD grades III–IV (CD3+ donors >95%) mainly post‐myeloablative conditioning regimen. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results